Rivera M P
Department of Pulmonary and Critical Care Medicine, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina 27599-7020, USA.
Curr Opin Pulm Med. 2001 Jul;7(4):247-58. doi: 10.1097/00063198-200107000-00014.
Lung cancer is one of the most lethal cancers, causing more deaths of men and women than any other cancer in the United States. Non-small-cell lung cancers account for most the newly diagnosed cases of lung cancer. Many patients with non-small-cell lung cancer present with advanced-stage disease and are not appropriate candidates for combined modality therapy. Although these patients have incurable disease, they have a chance of achieving improved 1-year survival rates and palliation of symptoms with chemotherapy. The performance status of patients with advanced non-small-cell lung cancer is the most important determinant of response to chemotherapy.
肺癌是最致命的癌症之一，在美国导致死亡的男性和女性人数超过任何其他癌症。非小细胞肺癌占肺癌新诊断病例的大多数。许多非小细胞肺癌患者就诊时已处于晚期，不适合采用综合治疗模式。尽管这些患者患有无法治愈的疾病，但他们有机会通过化疗提高1年生存率并缓解症状。晚期非小细胞肺癌患者的体能状态是化疗反应的最重要决定因素。
